Infectious diseases seriously endanger human health. Rapid and accurate detection of pathogens is the key to effective treatment and precise prevention and control of infectious diseases. Traditional pathogen testing techniques cover a limited variety of microorganisms, making it difficult to meet clinical needs. Metagenomic Next Generation Sequencing (mNGS) theoretically can simultaneously detect all known gene sequences of pathogens, greatly improving the clinical capacity of diagnosing and treating patients with severe, complicated, rare, and emerging pathogen infections. In the context of individualized health needs, the self-built testing of new technologies in laboratories can continuously improve the level of clinical diagnosis and treatment. Due to the high starting point of research and development and the complex operation process of the mNGS technology platform, this study reaches a consensus on the experimental procedure, assay validation, quality control, and report review of the mNGS-LDT in the fields of clinical testing, infection, critical care, and in vitro diagnosis to ensure the appropriate application of the technology and guarantee patient safety and proposes standardized requirements and suggestions.

Infectious diseases seriously endanger human health. Rapid and accurate detection of pathogens is the key to effective treatment and precise prevention and control of infectious diseases. Traditional pathogen testing techniques cover a limited variety of microorganisms, making it difficult to meet clinical needs. Metagenomic Next Generation Sequencing (mNGS) theoretically can simultaneously detect all known gene sequences of pathogens, greatly improving the clinical capacity of diagnosing and treating patients with severe, complicated, rare, and emerging pathogen infections. In the context of individualized health needs, the laboratory developed test(LDT) of new technologies in laboratories can continuously improve the level of clinical diagnosis and treatment. Due to the high starting point of research and development and the complex operation process of the mNGS technology platform, this study reaches a consensus on the experimental procedure, assay validation, quality control, and report review of the mNGS-LDT in the fields of clinical testing, infection, critical care, and in vitro diagnosis to ensure the appropriate application of the technology and guarantee patient safety and proposes standardized requirements and suggestions.

Infectious diseases seriously endanger human health. Rapid and accurate detection of pathogens is the key to effective treatment and precise prevention and control of infectious diseases. Traditional pathogen testing techniques cover a limited variety of microorganisms, making it difficult to meet clinical needs. Metagenomic Next Generation Sequencing (mNGS) theoretically can simultaneously detect all known gene sequences of pathogens, greatly improving the clinical capacity of diagnosing and treating patients with severe, complicated, rare, and emerging pathogen infections. In the context of individualized health needs, the laboratory developed test(LDT) of new technologies in laboratories can continuously improve the level of clinical diagnosis and treatment. Due to the high starting point of research and development and the complex operation process of the mNGS technology platform, this study reaches a consensus on the experimental procedure, assay validation, quality control, and report review of the mNGS-LDT in the fields of clinical testing, infection, critical care, and in vitro diagnosis to ensure the appropriate application of the technology and guarantee patient safety and proposes standardized requirements and suggestions.

Infectious diseases seriously endanger human health. Rapid and accurate detection of pathogens is the key to effective treatment and precise prevention and control of infectious diseases. Traditional pathogen testing techniques cover a limited variety of microorganisms, making it difficult to meet clinical needs. Metagenomic Next Generation Sequencing (mNGS) theoretically can simultaneously detect all known gene sequences of pathogens, greatly improving the clinical capacity of diagnosing and treating patients with severe, complicated, rare, and emerging pathogen infections. In the context of individualized health needs, the laboratory developed test(LDT) of new technologies in laboratories can continuously improve the level of clinical diagnosis and treatment. Due to the high starting point of research and development and the complex operation process of the mNGS technology platform, this study reaches a consensus on the experimental procedure, assay validation, quality control, and report review of the mNGS-LDT in the fields of clinical testing, infection, critical care, and in vitro diagnosis to ensure the appropriate application of the technology and guarantee patient safety and proposes standardized requirements and suggestions.

Infectious diseases seriously endanger human health. Rapid and accurate detection of pathogens is the key to effective treatment and precise prevention and control of infectious diseases. Traditional pathogen testing techniques cover a limited variety of microorganisms, making it difficult to meet clinical needs. Metagenomic Next Generation Sequencing (mNGS) theoretically can simultaneously detect all known gene sequences of pathogens, greatly improving the clinical capacity of diagnosing and treating patients with severe, complicated, rare, and emerging pathogen infections. In the context of individualized health needs, the laboratory developed test(LDT) of new technologies in laboratories can continuously improve the level of clinical diagnosis and treatment. Due to the high starting point of research and development and the complex operation process of the mNGS technology platform, this study reaches a consensus on the experimental procedure, assay validation, quality control, and report review of the mNGS-LDT in the fields of clinical testing, infection, critical care, and in vitro diagnosis to ensure the appropriate application of the technology and guarantee patient safety and proposes standardized requirements and suggestions.

Infectious diseases seriously endanger human health. Rapid and accurate detection of pathogens is the key to effective treatment and precise prevention and control of infectious diseases. Traditional pathogen testing techniques cover a limited variety of microorganisms, making it difficult to meet clinical needs. Metagenomic Next Generation Sequencing (mNGS) theoretically can simultaneously detect all known gene sequences of pathogens, greatly improving the clinical capacity of diagnosing and treating patients with severe, complicated, rare, and emerging pathogen infections. In the context of individualized health needs, the laboratory developed test(LDT) of new technologies in laboratories can continuously improve the level of clinical diagnosis and treatment. Due to the high starting point of research and development and the complex operation process of the mNGS technology platform, this study reaches a consensus on the experimental procedure, assay validation, quality control, and report review of the mNGS-LDT in the fields of clinical testing, infection, critical care, and in vitro diagnosis to ensure the appropriate application of the technology and guarantee patient safety and proposes standardized requirements and suggestions.

Infectious diseases seriously endanger human health. Rapid and accurate detection of pathogens is the key to effective treatment and precise prevention and control of infectious diseases. Traditional pathogen testing techniques cover a limited variety of microorganisms, making it difficult to meet clinical needs. Metagenomic Next Generation Sequencing (mNGS) theoretically can simultaneously detect all known gene sequences of pathogens, greatly improving the clinical capacity of diagnosing and treating patients with severe, complicated, rare, and emerging pathogen infections. In the context of individualized health needs, the laboratory developed test(LDT) of new technologies in laboratories can continuously improve the level of clinical diagnosis and treatment. Due to the high starting point of research and development and the complex operation process of the mNGS technology platform, this study reaches a consensus on the experimental procedure, assay validation, quality control, and report review of the mNGS-LDT in the fields of clinical testing, infection, critical care, and in vitro diagnosis to ensure the appropriate application of the technology and guarantee patient safety and proposes standardized requirements and suggestions.

Infectious diseases seriously endanger human health. Rapid and accurate detection of pathogens is the key to effective treatment and precise prevention and control of infectious diseases. Traditional pathogen testing techniques cover a limited variety of microorganisms, making it difficult to meet clinical needs. Metagenomic Next Generation Sequencing (mNGS) theoretically can simultaneously detect all known gene sequences of pathogens, greatly improving the clinical capacity of diagnosing and treating patients with severe, complicated, rare, and emerging pathogen infections. In the context of individualized health needs, the laboratory developed test(LDT) of new technologies in laboratories can continuously improve the level of clinical diagnosis and treatment. Due to the high starting point of research and development and the complex operation process of the mNGS technology platform, this study reaches a consensus on the experimental procedure, assay validation, quality control, and report review of the mNGS-LDT in the fields of clinical testing, infection, critical care, and in vitro diagnosis to ensure the appropriate application of the technology and guarantee patient safety and proposes standardized requirements and suggestions.

Infectious diseases seriously endanger human health. Rapid and accurate detection of pathogens is the key to effective treatment and precise prevention and control of infectious diseases. Traditional pathogen testing techniques cover a limited variety of microorganisms, making it difficult to meet clinical needs. Metagenomic Next Generation Sequencing (mNGS) theoretically can simultaneously detect all known gene sequences of pathogens, greatly improving the clinical capacity of diagnosing and treating patients with severe, complicated, rare, and emerging pathogen infections. In the context of individualized health needs, the laboratory developed test(LDT) of new technologies in laboratories can continuously improve the level of clinical diagnosis and treatment. Due to the high starting point of research and development and the complex operation process of the mNGS technology platform, this study reaches a consensus on the experimental procedure, assay validation, quality control, and report review of the mNGS-LDT in the fields of clinical testing, infection, critical care, and in vitro diagnosis to ensure the appropriate application of the technology and guarantee patient safety and proposes standardized requirements and suggestions.

Vaccination is one of the critical tools to prevent infections among individuals with autoimmune rheumatic diseases (ARDs), ultimately improving the quality of life and reducing mortality. The incorporation of vaccination strategies into clinical decision-making processes has been recognized as pivotal. However, the absence of clinical guidelines and consensus on vaccination for ARDs patients still persists in China. Drawing from existing clinical evidence, this expert consensus encompasses eight prevalent vaccines: Influenza vaccine, pneumococcal polysaccharide vaccine, COVID-19 vaccine, herpes zoster vaccine, human papillomavirus vaccine, hepatitis A vaccine, hepatitis B vaccine, and rabies virus vaccine. This initiative aims to furnish highly practical technical directives for vaccination personnel and rheumatologists, thereby fostering standardized vaccination practices to combat infectious diseases among adult ARDs patients in China.